Table 2. Univariate analysis of factors influencing the overall survival of patients with MF-CCA.

Factors		Survival Time (Months)		p
	Events (death)	Median	5-Year (%)
Gender				0.589
Male (n = 38)	29	18.51	20.9
Female (n = 58)	47	14.14	13.7
Age				0.670
≤ (n = 46)	35	14.70	20.4
>60 (n = 50)	41	14.53	12.3
Symptoms				0.002*
Negative (n = 16)	8	46.26	43.0
Positive (n = 80)	68	12.99	11.6
AST (IU/L)				0.243
≤34 (n= 51)	37	14.40	22.2
>34 (n = 43)	37	15.85	11.6
ALT (IU/L)				0.426
≤36 (n = 54)	40	14.53	19.4
>36 (n = 35)	31	15.85	9.8
ALP (IU/L)				0.001*
≤94 (n = 36)	23	26.86	27.5
>94 (n = 55)	50	10.72	9.1
Bilirubin (total) (mg/dL)				0.392
≤ 1.3(n = 82)	64	15.81	16.8
>1.3 (n = 14)	12	10.72	14.3
Albumin (g/dL)				0.023*
≤3.5 (n = 23)	20	5.75	13
>3.5 (n = 65)	51	19.89	15
Serum CEA (ng/dL)				0.030*
≤5 (n = 37)	26	19.17	22.6
>5 (n = 35)	31	12.72	8.9
Margin				<0.001*
Negative (n = 71)	51	19.89	22.8
Positive (n = 25)	25	4.70	0
Size				0.006*
≤5cm (n = 41)	27	20.88	29.1
>5cm (n = 52)	46	12.89	7.4
Lymph node				0.016*
Negative (n = 63)	47	20.88	18.4
Positive (n = 31)	27	12.72	12.9
Histological differentiation				0.960
Well (n = 3)	2	6.08	33.3
Moderate (n = 48)	38	15.81	18.6
Poor (n = 43)	34	14.40	14.6
Others (n = 2)	2	10.72	0
SPHK 1 expression				<0.001*
Low (n = 32)	18	43.50	40.4
High (n = 64)	58	9.11	4.0
Post-op Chemotherapy				0.383
Without (n = 48)	33	14.40	23.8
With (n = 48)	43	14.70	10.4
Post-op Radiotherapy				0.075
Without (n = 84)	64	14.53	19.2
With (n = 12)	12	7.17	0

CI: confidence interval; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; IU: international unit; op: operation